


<https://doi.org/10.1038/s41531-025-00896-2>

The *LRRK2* p.L1795F variant causes Parkinson's disease in the European population



Lara M. Lange^{1,2,3}✉, Kristin Levine^{4,5}, Susan H. Fox⁶, Connie Marras⁶, Nazish Ahmed⁶, Nicole Kuznetsov^{4,5}, Dan Vitale^{4,5}, Hirotaka Iwaki^{3,4,5}, Katja Lohmann¹, Luca Marsili⁷, Alberto J. Espay⁷, Peter Bauer⁸, Christian Beetz⁸, Jessica Martin⁵, Stewart A. Factor⁹, Lenora A. Higginbotham⁹, Honglei Chen¹⁰, Hampton Leonard^{4,5}, Mike A. Nalls^{4,5}, Niccolo E. Mencacci¹¹, Huw R. Morris^{12,13}, Andrew B. Singleton^{3,5}, Christine Klein^{1,2}, Cornelis Blauwendraat^{3,5}, Zih-Hua Fang¹⁴✉ & the Global Parkinson's Genetics Program (GP2)*

LRRK2-PD represents the most common form of autosomal dominant Parkinson's disease. We identified the *LRRK2* p.L1795F variant in three families and six additional unrelated cases using genetic data from over 50,000 individuals. Carriers with available genotyping data shared a common haplotype. The clinical presentation resembles other *LRRK2*-PD forms. Combined with published functional evidence showing strongly enhanced *LRRK2* kinase activity, we provide evidence that *LRRK2* p.L1795F is pathogenic.

Pathogenic variants in the *LRRK2* gene are among the most common causes of autosomal dominant Parkinson's disease (PD)^{1,2} and are thought to act through a gain-of-function mechanism that increases kinase activity³. The *LRRK2* p.L1795F variant (chr12:40322386:G>T, hg38, rs111910483) has been shown to significantly enhance kinase activity, supporting its pathogenic role⁴. It was previously identified in eight PD cases from 2007 to 2019^{5–7}, and most recently 2024⁸ as well as suggested as a genetic risk factor with an odds ratio (OR) of 2.5⁹. However, insufficient evidence of segregation precluded this variant from being considered “pathogenic”. Determining pathogenicity is crucial for diagnosis, genetic counseling, and even more for treatment, particularly now that *LRRK2*-specific clinical trials are underway^{10,11}.

We screened a large cohort of PD cases and controls with short-read whole-genome sequencing (WGS) data, including 16,351 individuals from GP2 release 8 (DOI 10.5281/zenodo.13755496) and AMP-PD release 4 (for details see Methods and Supplementary Table 1) to identify recurrent rare

coding variants of unknown significance co-segregating with PD in known PD genes (*LRRK2*, *SNCA*, *VPS35*, *PINK1*, *PRKN*, *PARK7*, and *GBA1*). We identified nine carriers of the *LRRK2* p.L1795F variant (ENST00000298910.12:c.5385 G > T; chr12:40322386:G>T; Supplementary Figs. 1–6). Of these carriers, we identified two families based on kinship inference using genetic data (Fig. 1). The larger family (GP2-FAM-1) included four affected individuals showing the segregation of this variant with PD. The second family (AMP-FAM-1) consisted of three carriers, one clinically affected with PD and two asymptomatic carriers (at ages 55 and 76 years, respectively). The remaining two carriers were PD cases with a positive family history of PD, but no additional family members were available for genetic testing. Notably, rs111910483 is multiallelic, and we identified 7 additional carriers of the synonymous p.L1795L (ENST00000298910.12:c.5385 G > A; chr12:40322386:G>A) variant. However, this synonymous variant is very unlikely to be disease-causing and was therefore excluded from any further analyses. Additionally, we did not

¹Institute of Neurogenetics, University of Luebeck, Luebeck, Germany. ²Department of Neurology, University Hospital Schleswig-Holstein, Luebeck, Germany.

³Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. ⁴DataTecnica, Washington, DC, USA. ⁵Center for

Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health,

Bethesda, MD, USA. ⁶Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital,

University Health Network, University of Toronto, Toronto, ON, Canada. ⁷University of Cincinnati, Cincinnati, OH, USA. ⁸CENTOGENE GmbH, Rostock, Germany.

⁹Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA. ¹⁰Department of Epidemiology and Biostatistics, Michigan State University,

Michigan, MI, USA. ¹¹Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ¹²Department of Clinical and Movement

Neurosciences, UCL Queen Square Institute of Neurology, London, UK. ¹³UCL Movement Disorders Centre, University College London,

London, UK. ¹⁴German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany. *A list of authors and their affiliations appears at

the end of the paper. ✉e-mail: la.lange@uni-luebeck.de; Zih-Hua.Fang@dzne.de






Fig. 1 | Pedigrees of identified families in this study. Pedigree of Family GP2-FAM-1 (A), CANADA-FAM-1 (B), and AMP-FAM-1 (C) with the *LRRK2* p.L1795F variant. The pedigrees were drawn based on reported family history and may be incomplete. The index cases are indicated with arrows. Affected individuals are indicated by black symbols: circles (female) and squares (male). Diamond is where sex is undefined. Unaffected individuals are indicated by open symbols. Unaffected variant carriers are indicated by open symbols with a dot in the middle. A diagonal line indicates deceased individuals. Red circle indicates individuals with genetic data available (WGS data for GP2-FAM-1 and AMP-FAM-1, single gene testing for CANADA-FAM-1). Heterozygous mutant (m) and wild-type (wt) genotypes are indicated with corresponding age at the sample collection (age) and age at motor symptom onset (if known; AAO). **A** The mother of GP2-FAM-1 index was reported to have eight additional siblings (#), several of whom are clinically affected with PD; however, no detailed family history is available for these relatives. **B** One maternal aunt (II-1) of the CANADA-FAM-1 index was reported to have had Alzheimer's disease (##).

with four individuals carrying the *LRRK2* p.L1795F variant, three of whom were PD cases and one being an asymptomatic carrier. In total, we identified 17 individuals carrying this variant across all the datasets, including nine index cases with PD as well as five affected and three unaffected family members.

The demographic and clinical details of all identified variant carriers are displayed in Table 1. More than two-thirds were females (70.6%; $n = 12/17$). All affected and unaffected carriers had a positive family history of PD. Notably, among the six singleton cases, two reported only second-degree relatives with PD, while three reported a multi-incident family history of the disease. Ages of motor symptom onset (AAO) in affected individuals ranged from 36 to 66 years. The median AAO was 54.5 years (interquartile range 47–60 years). The asymptomatic carriers were 55, 76 and 76 years old, respectively, at the time of sample collection and clinical evaluation. Based on the available clinical data, the majority of affected individuals had classical PD with an asymmetric onset of symptoms and a good response to dopaminergic medication, and without obvious atypical signs suggestive of other diagnoses (missing data for up to 30%). Detailed data on non-motor symptoms and neuropsychiatric comorbidities were scarce. Cognition was reported to be unaffected in the majority of affected carriers with good scores in cognition tests (including Montreal Cognitive Assessment [MoCA] and Mini Mental State Examination [MMSE]); however, one clinically affected individual had significant cognitive impairment (MoCA score of 17 points) and one unaffected carrier also showed some cognitive deficits (MoCA score of 23 points). More detailed characteristics of the individuals from the three identified families are available in the Supplementary Material.

The p.L1795F (ENST00000298910.12:c.5385 G > T) variant is currently categorized as a variant of uncertain significance in ClinVar and shows conflicting evidence from various *in-silico* prediction tools and databases (Supplementary Table 2 and Supplementary Fig. 9). It is rare and confined to European populations in several investigated databases (including gnomAD v4.1, the Regeneron Genetics Center Million Exome Variant Browser¹³, and the UK Biobank¹⁴ 500 K genomes). Similarly, all identified *LRRK2* p.L1795F carriers in this study were of European ancestry, whereas the variant was absent in other ancestral populations ($n = 15,316$) within the GP2 genotyping cohort. In Europeans, it had an allele frequency of 0.00012 among PD cases (5 heterozygous carriers and 20,812 noncarriers) while being absent in controls ($n = 9,032$; Table 2). The logistic regression analysis using the European population of the GP2 genotyping cohort did not reveal a significant association between this variant and PD, likely due to insufficient controls available in the dataset given its rarity ($P > 0.8$, Supplementary Table 3). When comparing the distribution of carriers between PD cases from the combined genotyping and WGS dataset (6 heterozygous carriers and 23,270 noncarriers) and two non-Finnish European control populations: gnomAD v3.1.2 non-neuro (0 heterozygous carriers and 31,960 noncarriers) and gnomAD v4.1 (2 heterozygous carriers and 589,826 noncarriers), this variant was significantly associated with PD ($P < 0.0056$ using gnomAD v3.1.2 non-neuro, and $P < 7.84 \times 10^{-8}$, OR = 76.04, 95% CI:

identify other recurrent variants in known PD genes with supporting segregation evidence.

Next, we screened the genotyping data of 54,153 affected and unaffected individuals generated within GP2 (DOI: 10.5281/zenodo.10962119), where the *LRRK2* p.L1795F variant was directly genotyped using the Neurobooster array. We identified three additional clinically affected variant carriers (Supplementary Fig. 7). We further screened the clinical exome data from 10,454 individuals from PDGENE which resulted in one additional variant carrier (Supplementary Fig. 8). Finally, querying the CEN-TOGENE proprietary Databank CentoMD¹², we identified another family

Table 1 | Demographic and clinical characteristics of identified *LRRK2* p.L1795F variant carriers

Cohort	GP2		AMP-PD								PDGENE		CANADA					
	Family ID		NA		NA		NA		NA		AMP-FAM-1		CANADA-FAM-1		CANADA			
	GP2-ID-1	GP2-ID-2	GP2-ID-3	GP2-ID-4	GP2-ID-5	GP2-ID-6	GP2-ID-7	GP2-ID-8	AMP-ID-1	AMP-ID-2	AMP-ID-3	AMP-ID-4	PDGENE-ID-1	CANADA-ID-1	CANADA-ID-2	CANADA-ID-3	CANADA-ID-4	
Sample ID	GP2-ID-1	GP2-ID-2	GP2-ID-3	GP2-ID-4	GP2-ID-5	GP2-ID-6	GP2-ID-7	GP2-ID-8	AMP-ID-1	AMP-ID-2	AMP-ID-3	AMP-ID-4	PDGENE-ID-1	CANADA-ID-1	CANADA-ID-2	CANADA-ID-3	CANADA-ID-4	
Genetic method	NBA, WGS	NBA, WGS	NBA, WGS	NBA, WGS	NBA, WGS	NBA, WGS	NBA, WGS	NBA, WGS	WGS	WGS	WGS	WGS	CES	Single gene testing (<i>LRRK2</i>)				
Demographics																		
Gender	Female	Female	Male	Female	Male	Male	Female	Male	Female	Female	Female	Female	Female	Female	Male	Female	Female	
Genetic ancestry	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	White	White	White	White	
Age at sample collection	78	74	66	68	42	72	62	76	76	55	54	69	57	76	75	55	54	
Family history of PD	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	
Family history details	two children, three sisters, one nephew, several aunts and uncles	three sisters, one niece and two nephews, several aunts and uncles	sister, mother, three maternal aunts	brother, mother, three maternal aunts	aunt, two great uncles	mother, brother	mother, sister	mother	father, two siblings, child	sibling, maternal grand-parent, maternal aunt	maternal grand-parent, two maternal aunts	mother	maternal grand-mother	father, two siblings, two children	father, two siblings, two nieces	sibling, two maternal uncles, maternal grandfather	sibling, two maternal uncles, maternal grandfather	
Clinical data																		
Diagnosis	PD	PD	PD	PD	PD	PD	PD	PD	Control*	Control*	PD*	PD	PD	Control**	PD	PD	PD	
AAO	55	54	58	50	36	60	57	55	NA	NA	46	65	47	NA	65	66	44	
AAE	78	74	67	68	42	72	62	76	76	55	54	69	57	76	75	67	66	
Bradykinesia	+	+	+	+	+	+	+	+	NA	NA	+	+	+	-	+	+	+	
Rigidity	+	+	+	+	+	-	+	+	NA	NA	+	+	+	-	-	+	+	
Resting Tremor	+	+	+	+	+	+	-	+	NA	NA	+	+	-	-	+	-	-	
Action/Kinetic Tremor	+	+	+	+	-	+	+	NA	NA	NA	-	+	-	-	-	+	+	
Postural Instability	+	+	-	+	+	-	+	+	NA	NA	-	-	-	-	-	-	+	
Gait Disturbance	+	+	-	+	+	-	-	NA	NA	NA	-	+	-	-	-	+	+	
Asymmetric onset of symptoms	+	+	+	+	+	+	+	NA	NA	NA	+	NA	+	-	+	-	+	
Responsive to dopaminergic medication	+	+	+	+	+	+	+	NA	NA	NA	+	NA	+	NA	NA	NA	+	
Fluctuations	NA	NA	+	+	-	NA	NA	NA	NA	NA	+	NA	+	-	-	-	+	
UPDRS Part III (motor score)	70	NA	10	22	24	6	11	NA	NA	NA	3	32	6	0	6	7	43	
Hoehn & Yahr	5	2	2	2	2	1	1.5	NA	NA	NA	2	2	2	0	1	0	3	
Cognition	MMSE 29	MMSE 29	MMSE 30	MMSE 30	MMSE 30	MMSE 30	MMSE 30	NA	NA	NA	MoCA 28	NA	-	MoCA 23	MoCA 17	MoCA 29	MoCA 28	
Neuro-psychiatric features	NA	NA	-	-	NA	NA	NA	NA	NA	NA	NA	NA	-	NA	NA	-	+	

Table 1 (continued) | Demographic and clinical characteristics of identified *LRRK2* p.L1795F variant carriers

Cohort	GP2		AMP-PD				PDGENE		CANADA	
	Family ID	GP2-FAM-1	-	-	NA	NA	AMP-FAM-1	NA	-	CANADA-FAM-1
Dysautonomia	-	-	-	constipation	NA	-	NA	NA	-	-
Atypical Features or signs suggestive of other diagnosis (#)	history of head trauma with loss of consciousness	-	-	history of head trauma with loss of consciousness	NA	-	NA	NA	-	-

+ present; - absent.
AAE age at clinical examination, AAO age at motor symptom onset, EUR European, MMSE Mini Mental State Examination, MOCA Montreal Cognitive Assessment, NA Not available or applicable, NBA NeuroBooster Array, PD Parkinson's disease, CES clinical-exome sequencing, WGS Whole-genome sequencing.
*Individuals were recruited through the LCC as "Genetically enriched" study arm.
**Recruited as unaffected family member, not population control.
(#) These include: history of strokes or stepwise deterioration, history of head injury with loss of consciousness, history of encephalitis, Oculogyric crisis, neuroleptic treatment at time of symptom onset, sustained remission, gaze palsy, Cerebellar signs (other than activation tremor), Fluctuations, hallucinations, dysautonomia, Memory loss, or prominent axial rigidity.

15.35–376.77 using gnomAD v4.1, two-tailed Fisher’s exact test). Given this variant was observed only in the European population, we searched for the overlapping IBD segments among the variant carriers using the genotyping data. The median length of an IBD segment over *LRRK2* in these individuals was 7.05 cM (range: 2.1–96.3 cM, Fig. 2). All genotyped carriers shared a core haplotype of 2.825 Mbp at this locus (Supplementary Table 4), suggesting that the p.L1795F variant descended from a common founder.

To our knowledge, we provide the largest number of *LRRK2* p.L1795F variant carriers thus far, including 14 carriers clinically affected with PD and three asymptomatic carriers. The available data from the previously reported carriers^{5–8} do not align with our data, making an overlap of individuals between the studies unlikely. Including those reported in the literature, this brings the total to 22 clinically affected carriers of European ancestry. Still, the overall number of p.L1795F carriers is limited, and higher frequencies might be observed in specific European subpopulations. Our haplotype analysis indicating a common founder further supports this hypothesis, although we were only able to determine the geographical origin of one family of carriers in this study, which was of Ukrainian and Polish descent. Taken together with four recently published carriers of either Hungarian or Slovak origin, this likely indicates a Central-Eastern European origin⁸. Notably, we identified three asymptomatic p.L1795F carriers, who might still develop PD symptoms later in life. However, given the pedigree structure of these individuals, this may also reflect reduced penetrance - a common phenomenon in monogenic forms of PD, including other pathogenic *LRRK2* variants.

Comparing the clinical phenotypes of p.L1795F carriers with those of other pathogenic *LRRK2* variants, particularly p.G2019S¹⁵, revealed similarities among them and with idiopathic PD (iPD). While group differences in clinical phenotypes among *LRRK2* variants may exist¹⁶, they do not enable meaningful genotype-phenotype correlations at an individual level. *LRRK2*-PD is clinically indistinguishable from iPD on an individual level. Most individuals with *LRRK2*-PD, including p.L1795F carriers, exhibit a classic PD phenotype with a good response to dopaminergic treatment. Atypical presentations have been described in single cases but are overall rare¹⁶. Notably, the p.L1795F variant is located in the COR-B domain, in close proximity to other pathogenic *LRRK2* variants, namely p.Y1699C¹⁷ and p.F1700L¹⁸. Interestingly, for p.Y1699C carriers, a more heterogeneous phenotype has been reported, including atypical signs like amyotrophy, dementia and symptoms of behavioral disorders.^{17,19–21} However, this observation might be coincidental and biased by the small number of variant carriers. Atypical features, prominent non-motor features, or neuropsychiatric comorbidities haven’t been specifically reported for the majority of p.L1795F carriers, but the overall data is limited, making it difficult to draw meaningful conclusions. Overall, the p.L1795F phenotype aligns well with the general characteristics of *LRRK2*-PD and appears comparable to other *LRRK2* variants with cautious interpretation given the limited number of identified carriers. The most significant differences between the genetic subtypes are their ancestral and geographical variability.

In conclusion, this is the first study providing evidence of the *LRRK2* p.L1795F variant segregating with disease in multiplex families, missing from the previous reports^{5–8}. Taken together with published functional data⁴, showing strongly enhanced *LRRK2* kinase activity, our findings support the *LRRK2* p.L1795F variant to be considered pathogenic. Large-scale studies can be helpful to identify novel rare causes of PD but also to re-evaluate previously identified variants by providing additional evidence of pathogenicity through an increased number of variant carriers and segregation. We therefore propose *LRRK2* p.L1795F as a cause of PD, especially in the European population. Including this variant in the genetic screening of PD patients, particularly those of Central-Eastern European origin, may be beneficial for the variant carriers to be included in ongoing gene-specific clinical trials.

Methods

Ethics declaration

This study was conducted in accordance with the ethical standards of the institutional and national research committees. This study was approved by

Table 2 | Frequency of the *LRRK2* p.L1795F and p.G2019S variants across ancestries in the GP2 genotyping cohort

Variant	Ancestry	AF in cases (allele count)	AF in controls (allele count)	Number of alleles in cases	Number of alleles in controls
chr12:40322386:G:T (<i>LRRK2</i> p.L1795F)	EUR	0.0001201 (5)	0 (0)	41634	18064
	AAC	0 (0)	0.0006281 (1)	568	1592
	AFR	0 (0)	0 (0)	1876	3252
	AJ	0.07081 (181)	0.01098 (9)	2556	820
	AMR	0.01339 (12)	0.003247 (1)	896	308
	CAH	0.006783 (7)	0.003436 (2)	1032	582
	CAS	0 (0)	0 (0)	1104	688
	EAS	0 (0)	0 (0)	5122	4752
	EUR	0.003266 (136)	0.000166 (3)	41636	18074
	FIN	0 (0)	0 (0)	192	14
	MDE	0.02805 (17)	0 (0)	606	446
	SAS	0 (0)	0 (0)	732	412

AF Allele frequency, AAC African admixed, AFR African, AJ Ashkenazi Jewish, AMR Latino and Indigenous people of the Americas, CAH Complex Admixture History, CAS Central Asian, EAS East Asian, EUR European, FIN Finnish, MDE Middle Eastern, SAS South Asian.
LRRK2: ENST00000298910.12; ENSP00000298910.7.




Fig. 2 | Overlapping identity-by-descent segments spanning *LRRK2* p.L1795F variant among the variant carriers with genotyping data. Each line represents an IBD segment inferred between a unique pair of individuals. IBD segments are colored based on whether both individuals in a pair belong to the same family (GP2-FAM-1) or are considered unrelated (UR). FS indicates an IBD segment between full siblings, 2nd degree refers to a segment between a pair of second-degree relatives, and PO represents a segment between a parent and offspring. The vertical grey line marks the genomic position of the *LRRK2* p.L1795F variant.

all ethics committees or institutional review boards of all sites participating in this study and providing samples and data, including the University of Cincinnati in Cincinnati (IRB#2017-5985), Ohio, USA, the Emory University School of Medicine in Atlanta, GA, USA, and the Michigan State University, MI, USA, and the University Health Network Research Ethics Board in Toronto, Canada. Informed consent for study participation was obtained from all participants.

Study design and participants

Our study workflow is highlighted in Fig. 3. Three sources of data were included in this study (Supplementary Table 1). First, we used the

multi-ancestry whole-genome sequencing and genotyping data from the study participants recruited as part of GP2²² (DOI 10.5281/zenodo.13755496) as previously described^{23,24}. Individual-level demographic and clinical data were obtained from participating principal investigators and publicly available databases (e.g., for Coriell samples included in GP2). Second, we incorporated whole-genome sequencing data from AMP-PD. Participants in this initiative were recruited through multiple studies, including BioFIND, the Harvard Biomarkers Study (HBS), the Lewy Body Dementia Case-Control Cohort (LBD), the Parkinson’s Disease Biomarkers Program (PDBP), the Parkinson’s Progression Markers Initiative (PPMI), the *LRRK2* Cohort Consortium (LCC), the Study of Isradipine as a Disease-Modifying Agent in Subjects with Early Parkinson Disease, Phase 3 (STEADY-PD3), and the Study of Urate Elevation in Parkinson’s Disease, Phase 3 (SURE-PD3). Clinical information and genetic samples from participants were obtained with appropriate written consent and local institutional and ethical approvals. Detailed information about these studies is available on the AMP-PD website (<https://amp-pd.org>) and the respective study websites. Third, we obtained the clinical exome sequencing data from PDGENE², a large multi-center study in North America providing genetic testing and counseling to more than 15,000 participants.

Whole-genome sequencing (WGS) data

We included 9974 samples with the sequence alignment data available from BioFIND, HBS, LBD, PDBP, PPMI, STEADY-PD3, and SURE-PD3 cohorts through the AMP-PD release for joint genotyping with the GP2 cohort (Supplementary Table 5). Due to the unavailability of sequence alignment data from the LCC cohort, we used AMP-PD release 4 data to screen for potential pathogenic variants in this cohort.

Additionally, the DNA samples from 5,926 participants from the GP2 cohort (GP2 Data Release 8, DOI 10.5281/zenodo.13755496, Supplementary Table 5) were genome sequenced to an average of 30x coverage with 150 bp paired-end reads following Illumina’s TruSeq PCR-free library preparation protocol. We followed the same functional equivalence pipeline²⁵ as AMP-PD to produce the sequence alignment against the GRCh38DH reference genome.

We used DeepVariant v1.6.1²⁶ (<https://github.com/google/deepvariant>) to generate the single-sample variant calls for a total of 15,900 samples in GP2 and AMP-PD and performed joint-genotyping using GLnexus v1.4.3 (<https://github.com/dnanexus-rnd/GLnexus>) with the preset DeepVariant WGS configuration²⁷. We set genotypes to be

Study design and workflow




Fig. 3 | Study design. Figure created with BioRender.com.

missing after variant quality control defined as genotype quality ≥ 10 , read depth ≥ 10 , and heterozygous allele balance between 0.2 and 0.8, and retained high-quality variants with a call rate > 0.95 after quality control. After the sample quality control following the quality metrics defined by AMP-PD²⁸, we retained 15,752 samples (AMP-PD and GP2 combined) for the downstream analyses (Supplementary Table 5). Variant annotation was performed with Ensembl Variant Effect Predictor v111 (<http://www.ensembl.org/info/docs/tools/vep/index.html>, RRID:SCR_007931)²⁹. We used KING v2.3.0 (<https://www.kingrelatedness.com>, RRID:SCR_009251)³⁰ to infer relatedness up to the second-degree relatives to confirm the known relationships and identify cryptic familial relationships. Genetic ancestry was determined using GenoTools v1.2.3 (<https://github.com/GP2code/GenoTools>) with the default settings³¹.

Genome-wide genotyping with the Neurobooster Array (GP2)

We screened the genotyping data published as part of GP2's Data Release 7³² (DOI: 10.5281/zenodo.10962119, Supplementary Table 6). Genotyping was performed by GP2 using the NeuroBooster Array (NBA; v.1.0, Illumina, San Diego, CA)³³. Raw genotyping data underwent quality control and genetic ancestry prediction using GenoTools v1.2.3 with the default settings³¹. The *LRRK2* p.L1795F variant was directly genotyped using NBA, and the quality of genotype calls was assessed by examining the signal intensity plots.

Clinical exome sequencing (PDGENeration)

We included 10,454 samples with clinical exome data available from PDGENE² as part of GP2's Data Release 8 (DOI 10.5281/zenodo.13755496)³². The sequence data processing followed the same pipeline of WGS data as mentioned above. We performed joint-genotyping using GLnexus v1.4.3 with the preset DeepVariant WES configuration and followed the same criteria for sample and variant quality control as for the WGS data.

Querying additional databases (CENTOGENE)

We queried the CENTOGENE proprietary Databank CentoMD^{®12} to identify potential additional variant carriers. CENTOGENE is a globally operating genetic diagnostic lab. Genetic data included in this manuscript was generated by exon-wise PCR amplification followed by Sanger sequencing.

Statistical analyses

To estimate the allele frequency of *LRRK2* p.L1795F variant in multi-ancestral populations, we analyzed the GP2 genotyping data, the largest available dataset in this study. We excluded related individuals and samples from targeted recruitment, such as *LRRK2* and *GBA1* variant carriers within specific efforts of PPMI and LCC. Subsequently, we performed an association analysis of this variant with PD using the European population. We fitted the logistic regression model with PD status as binary outcome variable and the covariates as the genotype of *LRRK2* p.L1795F variant, sex, age, family history, and the first six principal components to account for the population stratification. For cases, age at onset (AAO) or age at diagnosis was used, while for controls, age at sampling was used. Additionally, we merged GP2 genotyping data with the combined AMP-PD and GP2 WGS data, resulting in a cohort of 23,276 PD cases of European ancestry after excluding duplicated, related, and targeted recruitment samples as mentioned above. This allowed us to compare the carrier distribution between PD cases and non-Finnish European population from the Genome Aggregation Database (gnomAD v.3.1.2 non-neuro and v4.1, <http://gnomad.broadinstitute.org/>, RRID:SCR_014964) as external population controls using Fisher's exact test. We excluded the PDGENE clinical exome data from this analysis as we could not estimate the genetic ancestry in the same manner as with the other datasets. The P value ≤ 0.05 was considered statistically significant for all the analyses.

To determine if carriers of the *LRRK2* p.L1795F variant shared recent common ancestry, we phased the genotyping data from chromosome 12 in the European population using Beagle 5.4 (<https://faculty.washington.edu/browning/beagle/beagle.html>) with default settings³⁴ and searched for identical-by-descent (IBD) segments with the length ≥ 2 cM shared across the carriers using hap-ibd v1.0.0 (<https://github.com/browning-lab/hap-ibd>) with default setting³⁵.

Data availability

GP2 partnered with the online cloud computing platform Accelerating Medicines Partnership - Parkinson's Disease (AMP PD; <https://amp-pd.org>) to share data generated by GP2. Qualified researchers are encouraged to apply for direct access to the data through AMP PD. The GP2 and AMP-PD datasets analysed during the current study are available through AMP-PD (<https://amp-pd.org>). Additional data analysed during this study (Cen-togene) are included in this published article.

Code availability

All scripts used for this study can be found in the public domain on GitHub (https://github.com/GP2code/EUR_LRRK2_pL1795F).

Received: 20 July 2024; Accepted: 17 February 2025;

Published online: 25 March 2025

References

- Westenberger, A. et al. Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study. *Brain* **147**, 2652–2667 (2024).
- Cook, L. et al. Parkinson's disease variant detection and disclosure: PD GENeration, a North American study. *Brain* **147**, 2668–2679 (2024).
- Taylor, M. & Alessi, D. R. Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease. *Curr. Opin. Cell Biol.* **63**, 102–113 (2020).
- Kalogeropolou, A. F. et al. Impact of 100 *LRRK2* variants linked to Parkinson's disease on kinase activity and microtubule binding. *Biochem. J* **479**, 1759–1783 (2022).
- Nichols, W. C. et al. *LRRK2* mutation analysis in Parkinson disease families with evidence of linkage to PARK8. *Neurology* **69**, 1737–1744 (2007).
- Benitez, B. A. et al. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease. *Mol. Neurodegener.* **11**, 29 (2016).
- Illés, A. et al. The role of genetic testing in the clinical practice and research of early-onset parkinsonian disorders in a hungarian cohort: increasing challenge in genetic counselling, improving chances in stratification for clinical trials. *Front. Genet.* **10**, 1061 (2019).
- Ostrozovicova, M. et al. p.L1795F *LRRK2* variant is a common cause of Parkinson's disease in Central Europe. *Res. Sq.* <https://doi.org/10.21203/rs.3.rs-4378197/v1> (2024).
- Pitz, V. et al. Analysis of rare Parkinson's disease variants in millions of people. *NPJ Parkinsons Dis* **10**, 11 (2024).
- McFarthing, K. et al. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update. *J. Parkinsons. Dis.* **12**, 1073–1082 (2022).
- Kluss, J. H., Lewis, P. A. & Greggio, E. Leucine-rich repeat kinase 2 (*LRRK2*): an update on the potential therapeutic target for Parkinson's disease. *Expert Opin. Ther. Targets* **26**, 537–546 (2022).
- Trujillano, D. et al. A comprehensive global genotype-phenotype database for rare diseases. *Mol. Genet. Genomic Med.* **5**, 66–75 (2017).
- Sun, K. Y. et al. A deep catalog of protein-coding variation in 985,830 individuals. *bioRxiv* <https://doi.org/10.1101/2023.05.09.539329> (2023).
- Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* **12**, e1001779 (2015).
- MDSGene. *Movement Disorder Society Genetic mutation database (MDSGene)* <https://www.mdsgene.org/>.
- Saunders-Pullman, R., Raymond, D. & Elango, S. *LRRK2* Parkinson Disease. in *GeneReviews*[®] (eds. Adam, M. P. et al.) (University of Washington, Seattle, Seattle (WA), 2006).
- Zimprich, A. et al. Mutations in *LRRK2* cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron* **44**, 601–607 (2004).
- Borsche, M. et al. The New p.F1700L *LRRK2* variant causes Parkinson's disease by extensively increasing kinase activity. *Mov. Disord.* **38**, 1105–1107 (2023).
- Kim, J. S. et al. A Korean Parkinson's disease family with the *LRRK2* p.Tyr1699Cys mutation showing clinical heterogeneity. *Mov. Disord.* **27**, 320–324 (2012).
- Wszolek, Z. K. et al. German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia - Longitudinal observations. *Parkinsonism Relat. Disord.* **3**, 125–139 (1997).
- Khan, N. L. et al. Mutations in the gene *LRRK2* encoding dardarin (*PARK8*) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. *Brain* **128**, 2786–2796 (2005).
- Global Parkinson's Genetics Program. GP2: The Global Parkinson's Genetics Program. *Mov. Disord.* **36**, 842–851 (2021).
- Lange, L. M. et al. Elucidating causative gene variants in hereditary Parkinson's disease in the Global Parkinson's Genetics Program (GP2). *NPJ Parkinsons Dis* **9**, 100 (2023).
- Towns, C. et al. Defining the causes of sporadic Parkinson's disease in the global Parkinson's genetics program (GP2). *NPJ Parkinsons Dis.* **9**, 131 (2023).
- Regier, A. A. et al. Functional equivalence of genome sequencing analysis pipelines enables harmonized variant calling across human genetics projects. *Nat. Commun.* **9**, 1–8 (2018).
- Poplin, R. et al. A universal SNP and small-indel variant caller using deep neural networks. *Nat. Biotechnol.* **36**, 983–987 (2018).
- Yun, T. et al. Accurate, scalable cohort variant calls using DeepVariant and GLnexus. *Bioinformatics* **36**, 5582–5589 (2021).
- Iwaki, H. et al. Accelerating medicines partnership: Parkinson's disease. *Genetic Resource. Mov. Disord.* **36**, 1795–1804 (2021).
- McLaren, W. et al. The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).
- Manichaikul, A. et al. Robust relationship inference in genome-wide association studies. *Bioinformatics* **26**, 2867–2873 (2010).
- Vitale, D. et al. GenoTools: An Open-Source Python Package for Efficient Genotype Data Quality Control and Analysis. *bioRxiv* <https://doi.org/10.1101/2024.03.26.586362> (2024).
- Leonard, H. et al. Global Parkinson's Genetics Program data release 7. Zenodo <https://doi.org/10.5281/ZENODO.10962119> (2024).
- Bandres-Ciga, S. et al. NeuroBooster Array: a genome-wide genotyping platform to study neurological disorders across diverse populations. *medRxiv* <https://doi.org/10.1101/2023.11.06.23298176> (2023).
- Browning, B. L., Tian, X., Zhou, Y. & Browning, S. R. Fast two-stage phasing of large-scale sequence data. *Am. J. Hum. Genet.* **108**, 1880–1890 (2021).
- Zhou, Y., Browning, S. R. & Browning, B. L. A fast and simple method for detecting identity-by-descent segments in large-scale data. *Am. J. Hum. Genet.* **106**, 426–437 (2020).

Acknowledgements

Genotyping data and whole-genome sequencing data (DOI: 10.5281/zenodo.10962119, Release 7 and DOI 10.5281/zenodo.13755496,

Release 8) used in the preparation of this article were obtained from Global Parkinson's Genetics Program (GP2). GP2 is funded by the Aligning Science Against Parkinson's (ASAP) Initiative and implemented by The Michael J. Fox Foundation for Parkinson's Research (<https://www.gp2.org>). For a complete list of GP2 members see <http://www.gp2.org>. Whole-genome sequencing data used in the preparation of this article were obtained from the Accelerating Medicine Partnership® (AMP®) Parkinson's Disease (AMP PD) Knowledge Platform. For up-to-date information on the study, visit <https://www.amp-pd.org>. The AMP® PD program is a public-private partnership managed by the Foundation for the National Institutes of Health and funded by the National Institute of Neurological Disorders and Stroke (NINDS) in partnership with the Aligning Science Across Parkinson's (ASAP) initiative; Celgene Corporation, a subsidiary of Bristol-Myers Squibb Company; GlaxoSmithKline plc (GSK); The Michael J. Fox Foundation for Parkinson's Research; Pfizer Inc.; AbbVie Inc.; Sanofi US Services Inc.; and Verily Life Sciences. ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services. Clinical data used in preparation of this article were obtained from the MJFF-sponsored LRRK2 Cohort Consortium (LCC). For up-to-date information on the study, visit www.michaeljfox.org.lcc. The LRRK2 Cohort Consortium is coordinated and funded by The Michael J. Fox Foundation for Parkinson's Research. The investigators within the LCC provided data, but did not participate in the analysis or writing of this report. The full list of LCC investigators can be found at www.michaeljfox.org/lccinvestigators. PD GENERation is a study funded by the Parkinson's Foundation and supported by GP2, a program of Aligning Science Across Parkinson's (ASAP). Variant queries in the UKBB were conducted under approved project 82590 (to Z.-H.F.). Additional data used for this article was obtained from PD GENERation. PD GENERation is a study funded by the Parkinson's Foundation and supported by GP2, a program of Aligning Science Across Parkinson's (ASAP). This work was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services, project ZIA AG000949.

Author contributions

L.M.L. and Z.-H.F. were responsible for the study conceptualization and execution. They analyzed and interpreted the generated genotyping, clinical-exome, and whole-genome sequencing data and wrote the first draft of the manuscript. L.M.L. analyzed and interpreted the clinical data. Z.-H.F. performed sequencing data processing. H.I., J.M., N.K., K.Le., D.V., H.L., M.A.N., and C.B. were involved in sample and genotyping data acquisition and access to raw data. K.Lo., N.E.M., A.B.S., C.K., and C.B. contributed to the genetic data analysis and interpretation. H.I., H.R.M., and C.K. contributed to clinical data collection and analysis. L.M., A.E., and H.C. contributed samples from affected individuals to GP2 that were identified to carry the *LRRK2* variant and their respective demographic and clinical data included in this manuscript. S.A.F. and L.A.H. contributed clinical and genetic data generated as part of the PDGENERation study. S.F., N.A., and C.M. contributed clinical data for individuals included in this study. P.B. and C.B. contributed genetic data generated by CENTOGENE GmbH. All co-authors read and approved the final version of the manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Competing interests

L.M.L., N.A., K. Lo., and L.A.H. declare no competing interests. C.M. receives research funding from the Michael J Fox Foundation, the Parkinson's Foundation (US) and holds the Catherine Manson Chair in Movement Disorders, funded by the Mayvon Foundation. D.V., H.L.L., H.I., K.Le., and M.A.N.'s participation in this project was part of a

competitive contract awarded to DataTecnica LLC by the National Institutes of Health to support open science research. M.A.N. also currently serves on the scientific advisory board for Character Bio Inc plus is a scientific founder at Neuron23 Inc and owns stock. L.M. has received honoraria from the International Association of Parkinsonism and Related Disorders (IAPRD) Society for social media and web support, and personal compensation as a consultant/scientific advisory board member for Acadia. He has received a grant (collaborative research agreement) from the International Parkinson and Movement Disorders Society for the MDS-UTRS Validation Program (Role: PI), Non-Profit. A.J.E. has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Neuroderm, Amneal, Acadia, Avion Pharmaceuticals, Acorda, Kyowa Kirin, Supernus (formerly, USWorldMeds), Neuro-Diagnostics, Inc (SYNAPS Dx), Intrance Medical Systems, Inc., Praxis Precision Medicines, and Herantis Pharma; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He co-founded REGAIN Therapeutics and is co-inventor of the patent "Compositions and methods for treatment and/or prophylaxis of proteinopathies. P.B. and C.B. are employees of CENTOGENE GmbH. S.A.F. received honoraria from Lundbeck, Biogen, Takeda, and Neurocrine and grants from Medtronic, Boston Scientific, Sun Pharmaceuticals Advanced Research Company, Aspen, Biohaven, Neurocrine, Voyager, Prilenia Therapeutics, CHDI Foundation, Michael J. Fox Foundation, NIH 1 P50 NS123103-01, NIH 1R01NS125294-01, and the Parkinson Foundation. Finally, he reports royalties from Demos, Blackwell Futura, Springer for textbooks, and Uptodate. N.E.M. receives salary and research support from the NIH (1K08NS131581), the Parkinson's Foundation and the Aligning Science Across Parkinson's (ASAP) Global Parkinson's Genetics Program (GP2). He serves as a member of the PDGENERation steering committee. H.R.M. is employed by UCL. In the last months, he reports paid consultancies from Roche, Aprinolia, AI Therapeutics and Amylyx; lecture fees/honoraria from BMJ, Kyowa Kirin, and the Movement Disorders Society; and research Grants from Parkinson's UK, Cure Parkinson's Trust, PSP Association, Medical Research Council, and the Michael J Fox Foundation. H.R.M. is also a co-applicant on a patent application related to C9ORF72 - Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140). A.B.S. is an Associate Editor of Movement Disorders. He is an unpaid member of the Scientific Advisory Board of Cajal Neuroscience. C.K. has received grant support from The Michael J. Fox Foundation for Parkinson's Research and the Aligning Science Across Parkinson's Initiative. She serves as a medical advisor to Centogene, Retromer Therapeutics, and Takeda and received speakers' honoraria from Bial and Desitin. Z.-H.F. is supported by the Aligning Science Across Parkinson's (ASAP) Global Parkinson's Genetics Program (GP2) and receives GP2 salary support from The Michael J. Fox Foundation for Parkinson's Research. K.Lo., S.F., and A.B.S. are Associate Editors of npj Parkinson's disease. They were not involved in the journal's review of or decisions related to this manuscript.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41531-025-00896-2>.

Correspondence and requests for materials should be addressed to Lara M. Lange or Zih-Hua Fang.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2025

the Global Parkinson's Genetics Program (GP2)

Lara M. Lange^{1,2,3}✉, Kristin Levine^{4,5}, Dan Vitale^{4,5}, Hirotaka Iwaki^{3,4,5}, Katja Lohmann¹, Luca Marsili⁷, Alberto J. Espay⁷, Honglei Chen¹⁰, Hampton Leonard^{4,5}, Mike A. Nalls^{4,5}, Niccolo E. Mencacci¹¹, Huw R. Morris^{12,13}, Andrew B. Singleton^{3,5}, Christine Klein^{1,2}, Cornelis Blauwendraat^{3,5}, Zih-Hua Fang¹⁴✉, Emilia M. Gatto¹⁵, Marcelo Kauffman¹⁶, Samson Khachatryan¹⁷, Zaruhi Tavadyan¹⁷, Claire E. Shepherd¹⁸, Julie Hunter¹⁹, Kishore Kumar²⁰, Melina Ellis²¹, Miguel E. Rentería²², Sulev Koks²³, Alexander Zimprich²⁴, Artur F. Schumacher-Schuh²⁵, Carlos Rieder²⁶, Paula Saffie Awad²⁷, Vitor Tumas²⁸, Sarah Camargos²⁹, Edward A. Fon³⁰, Oury Monchi³¹, Ted Fon³², Benjamin Pizarro Galleguillos³³, Patricio Olguin³³, Marcelo Miranda³⁴, Maria Leonor Bustamante³⁵, Pedro Chana³⁶, Beisha Tang³⁷, Huifang Shang³⁸, Jifeng Guo³⁹, Piu Chan⁴⁰, Wei Luo⁴¹, Gonzalo Arboleda⁴², Jorge Orozco⁴³, Marlene Jimenez del Rio⁴⁴, Alvaro Hernandez⁴⁵, Mohamed Salama⁴⁶, Walaa A. Kamel⁴⁷, Yared Z. Zewde⁴⁸, Alexis Brice⁴⁹, Jean-Christophe Corvol⁵⁰, Ana Westenberger¹, Eva-Juliane Vollstedt¹, Harutyun Madoev¹, Joanne Trinh¹, Johanna Junker¹, Anastasia Illarionova¹⁴, Brit Mollenhauer⁵¹, Franziska Hopfner⁵², Günter Höglinger⁵², Manu Sharma⁵³, Thomas Gasser⁵³, Sergiu Groppa⁵⁴, Albert Akpalu⁵⁵, Georgia Xiromerisiou⁵⁶, Georgios Hadjigorgiou⁵⁶, Efthymios Dadiotis⁵⁶, Ioannis Dagklis⁵⁷, Ioannis Tarnanas⁵⁸, Leonidas Stefanis⁵⁹, Maria Stamelou⁶⁰, Alex Medina⁶¹, Germaine Hiu-Fai Chan⁶², Nelson Yuk-Fai Cheung⁶², Nancy Ip⁶³, Phillip Chan⁶³, Xiaopu Zhou⁶³, Asha Kishore⁶⁴, Divya KP⁶⁵, Pramod Pal⁶⁶, Prashanth Lingappa Kukkle⁶⁷, Roopa Rajan⁶⁸, Rupam Borgohain⁶⁹, Mehri Salari⁷⁰, Andrea Quattrone⁷¹, Monica Gagliardi⁷¹, Enza Maria Valente⁷², Micol Avenali⁷², Grazia Annesi⁷³, Lucilla Parnetti⁷⁴, Tommaso Schirinzi⁷⁵, Manabu Funayama⁷⁶, Nobutaka Hattori⁷⁶, Tomotaka Shiraishi⁷⁷, Altyay Karimova⁷⁸, Gulnaz Kaishibayeva⁷⁸, Cholpon Shambetova⁷⁹, Rejko Krüger⁸⁰, Ai Huey Tan⁸¹, Azlina Ahmad-Annur⁸¹, Shen-Yang Lim⁸¹, Yi Wen Tay⁸¹, Mohamed Ibrahim Norlinah⁸², Nor Azian Abdul Murad⁸³, Shahrul Azmin⁸⁴, Wael Mohamed⁸⁵, Daniel Martinez-Ramirez⁸⁶, Mayela Rodriguez-Violante⁸⁷, Paula Reyes-Pérez⁸⁸, Bayasgalan Tserensodnom⁸⁹, Rajeev Ojha⁹⁰, Tim J. Anderson⁹¹, Toni L. Pitcher⁹¹, Arinola Sanyaolu⁹², Njideka Okubadejo⁹², Oluwadamilola Ojo⁹², Jan O. Aasly⁹³, Lasse Pihlström⁹⁴, Manuela Tan⁹⁴, Shoaib Ur-Rehman⁹⁵, Mario Cornejo-Olivas⁹⁶, Maria Leila Doquenía⁹⁷, Raymond Rosales⁹⁷, Angel Vinuela⁹⁸, Elena Iakovenko⁹⁹, Bashayer Al Mubarak¹⁰⁰, Muhammad Umair¹⁰¹, Eng-King Tan¹⁰², Jia Nee Foo¹⁰³, Ferzana Amod¹⁰⁴, Jonathan Carr¹⁰⁵, Soraya Barden¹⁰⁵, Beomseok Jeon¹⁰⁶, Yun Joong Kim¹⁰⁷, Esther Cubo¹⁰⁸, Ignacio Alvarez¹⁰⁹, Janet Hoenicka¹¹⁰, Katrin Beyer¹¹¹, Maria Teresa Perinán¹¹², Pau Pastor¹¹³, Sarah El-Sadig¹¹⁴, Kajsa Brolin¹¹⁵, Christiane Zweier¹¹⁶, Paul Krack¹¹⁶, Gerd Tinkhauser¹¹⁷, Chin-Hsien Lin¹¹⁸, Pin-Jui Kung¹¹⁹, Hsiu-Chuan Wu¹²⁰, Ruey-Meei Wu¹¹⁸, Yihru Wu¹²⁰, Rim Amouri¹²¹, Samia Ben Sassi¹²¹, A. Nazlı Başak¹²², Özgür Öztıp Çakmak¹²², Sibel Ertan¹²², Gencer Genc¹²³, Alastair Noyce¹²⁴, Sumit Dey¹²⁴, Alejandro Martínez-Carrasco¹²⁵, Anette Schrag¹²⁵, Anthony Schapira¹²⁵, Eleanor J. Stafford¹²⁵, Henry Houlden¹²⁵, John Hardy¹²⁵, Kin Ying Mok¹²⁵, Mie Rizig¹²⁵, Nicholas Wood¹²⁵, Olaitan Okunoye¹²⁵, Rauan Kaiyrzhanov¹²⁵, Rimona Weil¹²⁵, Simona Jasaityte¹²⁵, Vida Obese¹²⁵, Camille Carroll¹²⁶, Claire Bale¹²⁷, Donald Grosset¹²⁸, Nigel Williams¹²⁹, Patrick Alfryn Lewis¹³⁰, Seth Love¹³¹, Simon Stott¹³², Caroline B. Pantazis¹³³, Kate Andersh¹³³, Laurel Screven¹³³, Sara Bandres-Ciga¹³³, Ignacio Juan Keller Sarmiento¹¹, Alyssa O'Grady¹³⁴, Bernadette Siddiqi¹³⁴, Bradford Casey¹³⁴, Brian Fiske¹³⁴, Charisse Comart¹³⁴, Justin C. Solle¹³⁴, Kaileigh Murphy¹³⁴, Maggie Kuhl¹³⁴, Naomi Louie¹³⁴, Sohini Chowdhury¹³⁴, Todd Sherer¹³⁴, Andrew K. Sobering¹³⁵, Cabell Jonas¹³⁶, Carlos Cruchaga¹³⁷, Laura Ibanez¹³⁷, Claire Wegel¹³⁸, Tatiana Foroud¹³⁹, Deborah Hall¹⁴⁰, Dena Hernandez¹³³, Jonggeol Jeff Kim¹³³, Yeajin Song¹³³, Ejaz Shiamim¹⁴¹, Ekemini Riley¹⁴², Geidy E. Serrano¹⁴³, Ignacio F. Mata¹⁴⁴, Miguel Inca-Martinez¹⁴⁴, Jared Williamson¹⁴¹, Joseph Jankovic¹⁴⁵, Joshua Shulman¹⁴⁵, Kamalini Ghosh Galvelis¹⁴⁶, Karen Nuytemans¹⁴⁷, Karl Kiebertz¹⁴⁸, Katerina Markopoulou¹⁴⁹, Kenneth Marek¹⁵⁰, Lana M. Chahine¹⁵¹, Lauren Ruffrage¹⁵², Lisa Shulman¹⁵³, Marissa Dean¹⁵², Matthew Farrer¹⁵⁴, Megan J. Puckelwartz¹⁵⁵, Steven Lubbe¹⁵⁵, Roger Albin¹⁵⁶, Roy Alcalay¹⁵⁷, Ruth Walker¹⁵⁸, Sonya Dumanis¹⁵⁹, Tao Xie¹⁶⁰, Thomas Beach¹⁶¹, Faraz Faghri¹³³,

Mary B. Makarious¹³³, Mathew Koretsky¹³³, Duan Nguyen¹⁶², Toan Nguyen¹⁶² & Masharip Atadzhonov¹⁶³

¹⁵Sanatorio de la Trinidad Mitre – INEBA, Buenos Aires, Argentina. ¹⁶Hospital JM Ramos Mejia, Buenos Aires, Argentina. ¹⁷Somnus Neurology Clinic, Yerevan, Armenia. ¹⁸Neuroscience Research Australia, Sydney, NSW, Australia. ¹⁹ANZAC Research Institute, Concord, NSW, Australia. ²⁰Garvan Institute of Medical Research and Concord Repatriation General Hospital, Darlinghurst, NSW, Australia. ²¹Concord Hospital, Concord, NSW, Australia. ²²QIMR Berghofer Medical Research Institute, Herston, QLD, Australia. ²³Murdoch University, Perth, Western Australia, Australia. ²⁴Medical University Vienna, Vienna, Austria. ²⁵Universidade Federal do Rio Grande do Sul / Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. ²⁶Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil. ²⁷Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. ²⁸University of São Paulo, São Paulo, Brazil. ²⁹Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. ³⁰Montreal Neurological Institute, Montreal, Quebec, Canada. ³¹Institut universitaire de gériatrie de Montréal, Montreal, Quebec, Canada. ³²McGill University, Montreal, Quebec, Canada. ³³Universidad de Chile, Santiago, Chile. ³⁴Fundación Diagnóstico, Santiago, Chile. ³⁵Faculty of Medicine Universidad de Chile, Santiago, Chile. ³⁶CETRAM, Santiago, Chile. ³⁷Central South University, Changsha, China. ³⁸West China Hospital Sichuan University, Chengdu, China. ³⁹Xiangya Hospital, Changsha, China. ⁴⁰Capital Medical University, Beijing, China. ⁴¹Zhejiang University, Hangzhou, China. ⁴²Universidad Nacional de Colombia, Bogotá, Colombia. ⁴³Fundación Valle del Lili, Santiago De Cali, Colombia. ⁴⁴University of Antioquia, Medellín, Colombia. ⁴⁵University of Costa Rica, San Jose, Costa Rica. ⁴⁶The American University in Cairo, Cairo, Egypt. ⁴⁷Beni-Suef University, Beni Suef, Egypt. ⁴⁸Addis Ababa University, Addis Ababa, Ethiopia. ⁴⁹Paris Brain Institute, Paris, France. ⁵⁰Sorbonne Université, Paris, France. ⁵¹University Medical Center Göttingen, Göttingen, Germany. ⁵²Department of Neurology, University Hospital, LMU Munich, Munich, Germany. ⁵³University of Tübingen, Tübingen, Germany. ⁵⁴University of Mainz, Mainz, Germany. ⁵⁵University of Ghana Medical School, Accra, Ghana. ⁵⁶University of Thessaly, Volos, Greece. ⁵⁷Aristotle University of Thessaloniki, Thessaloniki, Greece. ⁵⁸Ionian University, Corfu, Greece. ⁵⁹Biomedical research Foundation of the Academy of Athens, Athens, Greece. ⁶⁰Diagnostic and Therapeutic Centre HYGEIA Hospital, Marousi, Greece. ⁶¹Hospital San Felipe, Tegucigalpa, Honduras. ⁶²Queen Elizabeth Hospital, Kowloon, Hong Kong. ⁶³The Hong Kong University of Science and Technology, Kowloon, Hong Kong. ⁶⁴Aster Medcity, Kochi, India. ⁶⁵Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, India. ⁶⁶National Institute of Mental Health & Neurosciences, Bengaluru, India. ⁶⁷Manipal Hospital, Delhi, India. ⁶⁸All India Institute of Medical Sciences, Delhi, India. ⁶⁹Nizam's Institute Of Medical Sciences, Hyderabad, India. ⁷⁰Shahid Beheshti University of Medical Science, Tehran, Iran. ⁷¹Magna Graecia University of Catanzaro, Catanzaro, Italy. ⁷²University of Pavia, Pavia, Italy. ⁷³National Research Council, Cosenza, Italy. ⁷⁴University of Perugia, Perugia, Italy. ⁷⁵University of Rome Tor Vergata, Rome, Italy. ⁷⁶Juntendo University, Tokyo, Japan. ⁷⁷Jikei University School of Medicine, Tokyo, Japan. ⁷⁸Institute of Neurology and Neurorehabilitation, Almaty, Kazakhstan. ⁷⁹Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan. ⁸⁰University of Luxembourg, Luxembourg, Luxembourg. ⁸¹University of Malaya, Kuala Lumpur, Malaysia. ⁸²Universiti Kebangsaan Malaysia, Selangor, Malaysia. ⁸³UKM Medical Molecular Biology Institute, Kuala Lumpur, Malaysia. ⁸⁴Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia. ⁸⁵International Islamic University, Kuala Lumpur, Malaysia. ⁸⁶Tecnologico de Monterrey, Monterrey, Mexico. ⁸⁷Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico. ⁸⁸Universidad Nacional Autónoma de México, Mexico City, Mexico. ⁸⁹Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia. ⁹⁰Tribhuvan University, Kirtipur, Nepal. ⁹¹University of Otago, Dunedin, New Zealand. ⁹²University of Lagos, Lagos, Nigeria. ⁹³Norwegian University of Science and Technology, Trondheim, Norway. ⁹⁴Oslo University Hospital, Oslo, Norway. ⁹⁵University of Science and Technology Bannu, Bannu, Pakistan. ⁹⁶Universidad Científica del Sur, Lima, Peru. ⁹⁷Metropolitan Medical Center, Manila, Philippines. ⁹⁸University of Puerto Rico, San Juan, Puerto Rico. ⁹⁹Research Center of Neurology, Moscow, Russia. ¹⁰⁰King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. ¹⁰¹King Abdullah International Medical Research Center, Jeddah, Saudi Arabia. ¹⁰²National Neuroscience Institute, Singapore, Singapore. ¹⁰³Nanyang Technological University, Singapore, Singapore. ¹⁰⁴University of KwaZulu-Natal, Durban, South Africa. ¹⁰⁵Stellenbosch University, Stellenbosch, South Africa. ¹⁰⁶Seoul National University Hospital, Seoul, South Korea. ¹⁰⁷Yongin Severance Hospital, Seoul, South Korea. ¹⁰⁸Hospital Universitario Burgos, Burgos, Spain. ¹⁰⁹University Hospital Mutua Terrassa, Barcelona, Spain. ¹¹⁰Institut de Recerca Sant Joan de Deu, Barcelona, Spain. ¹¹¹Research Institute Germans Trias i Pujol, Barcelona, Spain. ¹¹²Instituto de Biomedicina de Sevilla, Seville, Spain. ¹¹³University Hospital Germans Trias i Pujol, Barcelona, Spain. ¹¹⁴Faculty of medicine university of Khartoum, Khartoum, Sudan. ¹¹⁵Lund University, Lund, Sweden. ¹¹⁶Inselspital Bern, University of Bern, Bern, Switzerland. ¹¹⁷University Hospital Bern, Bern, Switzerland. ¹¹⁸National Taiwan University Hospital, Taipei City, Taiwan. ¹¹⁹National Taiwan University, Taipei City, Taiwan. ¹²⁰Chang Gung Memorial Hospital, Taoyuan City, Taiwan. ¹²¹National Institute Mongi Ben Hamida of Neurology, Tunis, Tunisia. ¹²²Koç University, Istanbul, Turkey. ¹²³Şişli Etfal Training and Research Hospital, Istanbul, Turkey. ¹²⁴Queen Mary University of London, London, UK. ¹²⁵University College London, London, UK. ¹²⁶University of Plymouth, Plymouth, UK. ¹²⁷Parkinson's UK, London, UK. ¹²⁸University of Glasgow, Glasgow, UK. ¹²⁹Cardiff University, Cardiff, UK. ¹³⁰Royal Veterinary College University of London, London, UK. ¹³¹University of Bristol, Bristol, UK. ¹³²Cure Parkinson's, London, UK. ¹³³National Institutes of Health, Bethesda, MD, USA. ¹³⁴The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA. ¹³⁵Augusta University / University of Georgia Medical Partnership, Augusta, GA, USA. ¹³⁶Mid-Atlantic Permanente Medical Group, Bethesda, MD, USA. ¹³⁷Washington University, St. Louis, MO, USA. ¹³⁸Indiana University, Bloomington, IN, USA. ¹³⁹Indiana University School of Medicine, Indianapolis, IN, USA. ¹⁴⁰Rush University, Chicago, IL, USA. ¹⁴¹Kaiser Permanente, Oakland, CA, USA. ¹⁴²Coalition for Aligning Science, Washington, WA, USA. ¹⁴³Banner Sun Health Research Institute, Sun City, AZ, USA. ¹⁴⁴Cleveland Clinic, Cleveland, OH, USA. ¹⁴⁵Baylor College of Medicine, Houston, TX, USA. ¹⁴⁶Parkinson's Foundation, Princeton, NJ, USA. ¹⁴⁷University of Miami Miller School of Medicine, Miami, FL, USA. ¹⁴⁸Beth Israel Deaconess Medical Center, Boston, MA, USA. ¹⁴⁹North Shore University Health System, Chicago, IL, USA. ¹⁵⁰Institute for Neurodegenerative Disorders, New Haven, CT, USA. ¹⁵¹University of Pittsburgh, Pittsburgh, PA, USA. ¹⁵²University of Alabama at Birmingham, Birmingham, AL, USA. ¹⁵³University of Maryland, Baltimore, MD, USA. ¹⁵⁴University of Florida – Neurology, Gainesville, FL, USA. ¹⁵⁵Northwestern University, Chicago, IL, USA. ¹⁵⁶University of Michigan, Ann Arbor, MI, USA. ¹⁵⁷Columbia University, New York, NY, USA. ¹⁵⁸James J. Peters Veterans Affairs Medical Center, New York, NY, USA. ¹⁵⁹Aligning Science Across Parkinson's, Washington, WA, USA. ¹⁶⁰University of Chicago, Chicago, IL, USA. ¹⁶¹Sun Health Research Institution, Sun City, AZ, USA. ¹⁶²Hue University, Huế, Vietnam. ¹⁶³University of Zambia, Lusaka, Zambia.